ARCHIVES

Control-Arm CML Patients In Phase III Gleevec Study Allowed To Switch.

This article is from The Cancer Letter archive.

Vol. 28 No. 04 | January 25, 2002

Download PDF Visit The Full Archive

Related Articles

Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial

January 27, 2012

Abraxane-Gemcitabine Combination Extends Overall Survival in Phase III Trial

January 31, 2014

Has To Plan International Meeting On Threat If DNA Biohazards

September 13, 1974

Nutrition Program Announcement Lists Suggested Areas For Research

September 22, 1978

Roferon A Application Marred By Mission Data, Protocol, Compliance

September 24, 1999

Dear ASCO Member Letter From Klausner Attempts To Rescue Flagging BMT Trial.

June 2, 2000